Skip to main content
Article thumbnail
Location of Repository

Complement Lysis Activity in Autologous Plasma Is Associated with Lower Viral Loads during the Acute Phase of HIV-1 Infection

By Michael Huber, Marek Fischer, Benjamin Misselwitz, Amapola Manrique, Herbert Kuster, Barbara Niederöst, Rainer Weber, Viktor von Wyl, Huldrych F Günthard and Alexandra Trkola


Antibody-mediated complement lysis of HIV virions develops rapidly and is effective already early in the course of HIV infection

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (2003). Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.
    2. (2001). Analysis of total human immunodeficiency virus (HIV)-specific CD4 þ and CD8 þ T-cell responses: Relationship to viral load in untreated HIV infection.
    3. (1996). Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein.
    4. (2003). Antibody neutralization and escape by HIV-1.
    5. (2000). B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells.
    6. (2001). Cellular immune responses to HIV.
    7. (2004). Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef.
    8. (1995). Cervicovaginal overproduction of specific IgG to human immunodefi-ciency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection.
    9. (1987). Characterization and clinical association of antibody inhibitory to HIV reverse transcriptase activity.
    10. (1993). Complement activation by human monoclonal antibodies to human immunodeficiency virus.
    11. (1986). Complement activation in human lymph: modulation by the contact activation system and by leukocytes.
    12. (1989). Complement activation is associated with the presence of specific human immunodeficiency virus (HIV)-anti-HIV immune complexes in patients with acquired immunodeficiency syndrome-related complex or lymphoadenopathy syndrome.
    13. (1998). Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism.
    14. (1994). Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection.
    15. (2005). Complement dependent trapping of infectious HIV in human lymphoid tissues.
    16. (2004). Complement mediates the binding of HIV to erythrocytes.
    17. (2001). Complement. First of two parts.
    18. (2001). Complement. Second of two parts.
    19. (2004). Cutting edge: Productive HIV-1 infection of dendritic cells via complement receptor type 3 (CR3, CD11b/CD18).
    20. (2005). Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.
    21. (2005). Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodefi-ciency virus type 1 infection.
    22. (1999). Development of calibrated viral load standards for group m subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes.
    23. (1994). Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.
    24. (1997). Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. JVirol 71:
    25. (1991). Direct binding of complement component C1q to human immunodeficiency virus (HIV) and human T lymphotrophic virus-I (HTLV-I) coinfected cells.
    26. (1996). Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF,
    27. (1978). Engeset A
    28. (1995). Epitope exposure on functional, oligomeric HIV-1 gp41 molecules.
    29. (2004). Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene
    30. (1987). Evidence for activation of complement
    31. (1992). Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis.
    32. (1986). Hematologic correlates and the role of erythrocyte CR1 (C3b receptor) in the development of AIDS.
    33. (2003). Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies.
    34. (2005). HIV and human complement: Inefficient virolysis and effective adherence.
    35. (1994). Host cell components affect the sensitivity of HIV type 1 to complement-mediated virolysis.
    36. (1995). Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV).
    37. (2001). Human antibodies to major histocompatibility complex alloantigens mediate lysis and neutralization of HIV-1 primary isolate virions in the presence of complement.
    38. (1991). Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41.
    39. (1995). Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.
    40. (2002). Human immunodeficiency virus-specific CD8 þ T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy.
    41. (2004). Humoral immunity to HIV-1: Kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point.
    42. (1988). Hypocomplementemia and human immunodeficiency virus infection. Clinical correlates and relationships to circulating immune complex and immunoglobulin G levels.
    43. (1977). Immunoglobulins, complement and lysozyme in leg lymph of normal men.
    44. (1995). Interaction of several complement proteins with gp120 and gp41, the two envelope glycoproteins of HIV-1.
    45. (2004). Limited durability of viral control following treated acute HIV infection.
    46. (1990). Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis.
    47. (1996). Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.
    48. (2001). Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection.
    49. (2003). Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site.
    50. (1997). Passive immunization with a human monoclonal antibody protects huPBL- SCID mice against challenge by primary isolates of HIV-1.
    51. (2004). Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.
    52. (1995). Performance characteristics for the quantitation of plasma HIV-1 RNA using branched DNA signal amplification technology.
    53. (2000). Protection of macaques against vaginal transmission of a pathogenic HIV1/SIV chimeric virus by passive infusion of neutralizing antibodies.
    54. (2001). Quantification of in vitro retroviral replication using a one-tube real-time RT-PCR system incorporating direct RNA preparation.
    55. (2003). RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement.
    56. (2003). Rapid evolution of the neutralizing antibody response to HIV type 1 infection.
    57. (2002). Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts.
    58. (1995). Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1.
    59. (1994). Structure and polymorphism of the mouse prion protein gene.
    60. (1996). Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo.
    61. (2004). The complement system in regulation of adaptive immunity.
    62. (1994). The envelope glycoprotein of HIV-1 gp120 and human complement protein C1q bind to the same peptides derived from three different regions of gp41, the transmembrane glycoprotein of HIV-1, and share antigenic homology.
    63. (1999). The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity.
    64. (2004). The relevance of complement to virus biology.
    65. (2001). The supportive role of complement in HIV pathogenesis.
    66. (2005). Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.